Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | USP1 | O94782 | 6/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371675 | 0.87 | BRD4 (0.43) | BRD4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL13620291 | 0.86 | USP1 (0.41) | ADORA2AADORA1USP1TLR7ADORA3 | |
| SCHEMBL13620514 | 0.86 | BRD4 (0.43) | BRD4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL12371755 | 0.85 | ADORA2A (0.46) | ADORA2AADORA1USP1TLR7ADORA3 | |
| SCHEMBL13608397 | 0.84 | ADORA3 (0.44) | BRD4ADORA2AADORA1USP1TLR7 | |
| SCHEMBL12371731 | 0.83 | USP1 (0.44) | ADORA2AADORA1USP1TLR7ADORA3 | |
| SCHEMBL13620415 | 0.83 | HRH4 (0.45) | BRD4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL13620075 | 0.83 | BRD4 (0.43) | BRD4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL13620208 | 0.82 | BRD4 (0.40) | BRD4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL13620278 | 0.82 | BRD4 (0.42) | BRD4HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | BRD4 1920/4885HDAC3 2125/4885HDAC1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.